Tag: GlobeNewswire

Experienced technology and capital markets executive joins Pasqal to lead investor engagement and strengthen the company’s public-market presence following its Nasdaq listing

PARIS and NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, today announced the appointment of Roger L. Chuchen as Head of Investor Relations, as the company expands its commercial operations and global customer base following its Nasdaq listing in August 2026.

In this role, Roger will establish and lead Pasqal’s investor relations function, working closely with the company’s executive leadership team and Board of Directors to communicate Pasqal’s investment thesis, deepen engagement with institutional investors and analysts, and strengthen relationships with shareholders and the broader financial community. He will also oversee investor communications, market intelligence and disclosure-related activities, while helping articulate Pasqal’s long-term strategy and differentiated position in the rapidly evolving quantum computing market.

“Roger joins Pasqal at an important time in our evolution as a public company,” said Stéphane Rougeot, Chief Financial Officer of Pasqal. “As we scale our commercial operations, advance our technology roadmap and broaden our engagement with the global investment community, his extensive capital markets experience and deep understanding of the technology sector will be highly valuable. His ability to translate complex technologies and business strategies into clear investment narratives will further strengthen our dialogue with investors and analysts.”

Roger brings more than 25 years of experience across technology, investment management, equity research and corporate investor relations. Most recently, he served as Vice President of Investor Relations at AudioCodes, where he led the company’s investor engagement strategy and communications with the financial community. Earlier in his career, he held senior buy-side and sell-side positions at Citigroup Smith Barney (now Citi Research), Morgan Stanley Investment Management and J. Goldman & Co., L.P.

“Pasqal has established itself as a leading player in quantum computing, with a differentiated technology approach, growing commercial momentum and a clear long-term vision,” Roger said. “Becoming a public company creates an important opportunity to engage with a broader global investor base and increase understanding of the progress Pasqal is making across its technology, commercial and strategic priorities. I look forward to building the company’s investor relations function, strengthening engagement with investors and analysts, and supporting Pasqal’s continued growth.”

Contact:
Investors 
investors@pasqal.com

Media
pr@pasqal.com 

About Pasqal

Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

Forward-Looking Statements

Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project,” “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s evolution of the areas of its collaboration with the French public authorities and participation in the civil public support programs currently being defined.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations, including participation in government programs; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.

Experienced technology and capital markets executive joins Pasqal to lead investor engagement and strengthen the company’s public-market presence following its Nasdaq listing

PARIS and NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, today announced the appointment of Roger L. Chuchen as Head of Investor Relations, as the company expands its commercial operations and global customer base following its Nasdaq listing in August 2026.

In this role, Roger will establish and lead Pasqal’s investor relations function, working closely with the company’s executive leadership team and Board of Directors to communicate Pasqal’s investment thesis, deepen engagement with institutional investors and analysts, and strengthen relationships with shareholders and the broader financial community. He will also oversee investor communications, market intelligence and disclosure-related activities, while helping articulate Pasqal’s long-term strategy and differentiated position in the rapidly evolving quantum computing market.

“Roger joins Pasqal at an important time in our evolution as a public company,” said Stéphane Rougeot, Chief Financial Officer of Pasqal. “As we scale our commercial operations, advance our technology roadmap and broaden our engagement with the global investment community, his extensive capital markets experience and deep understanding of the technology sector will be highly valuable. His ability to translate complex technologies and business strategies into clear investment narratives will further strengthen our dialogue with investors and analysts.”

Roger brings more than 25 years of experience across technology, investment management, equity research and corporate investor relations. Most recently, he served as Vice President of Investor Relations at AudioCodes, where he led the company’s investor engagement strategy and communications with the financial community. Earlier in his career, he held senior buy-side and sell-side positions at Citigroup Smith Barney (now Citi Research), Morgan Stanley Investment Management and J. Goldman & Co., L.P.

“Pasqal has established itself as a leading player in quantum computing, with a differentiated technology approach, growing commercial momentum and a clear long-term vision,” Roger said. “Becoming a public company creates an important opportunity to engage with a broader global investor base and increase understanding of the progress Pasqal is making across its technology, commercial and strategic priorities. I look forward to building the company’s investor relations function, strengthening engagement with investors and analysts, and supporting Pasqal’s continued growth.”

Contact:
Investors 
investors@pasqal.com

Media
pr@pasqal.com 

About Pasqal

Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

Forward-Looking Statements

Certain statements herein may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “could,” “plan,” “predict,” “project,” “forecast,” “potential,” “seem,” “seek,” “target,” “possible,” “future,” “outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements include, but are not limited to, statements regarding future events, including Pasqal’s evolution of the areas of its collaboration with the French public authorities and participation in the civil public support programs currently being defined.

These statements are based on current expectations and are not predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and are beyond the control of Pasqal. These statements are subject to known and unknown risks and uncertainties and assumptions regarding Pasqal’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political, social and business conditions; uncertainty or changes with respect to laws and regulations, including participation in government programs; risks related to Pasqal’s indebtedness; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal does not know or currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Pasqal’s expectations, plans and forecasts of future events and views as of the date of this communication. While Pasqal may elect to update these forward-looking statements in the future, Pasqal specifically disclaims any obligation to do so.

NEW BRAUNFELS, Texas, Oct. 02, 2026 (GLOBE NEWSWIRE) — Rush Enterprises, Inc., (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America will host a conference call to discuss earnings for the third quarter 2026 on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central. Earnings will be reported after the close of market on Tuesday, October 27, 2026.

The call will be available at https://edge.media-server.com/mmc/p/exur5spz on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central.

Participants may register for the call at:
https://register-conf.media-server.com/register/BIb0ffed11621b4638812a165f5443c0ae
While not required, it is recommended that you join the event 10 minutes prior to the start.

For those who cannot listen to the live broadcast, the webcast replay will be available at http://investor.rushenterprises.com/events.cfm.

About Rush Enterprises, Inc.
Rush Enterprises, Inc. is the premier solutions provider to the commercial vehicle industry. The Company owns and operates Rush Truck Centers, the largest network of commercial vehicle dealerships in North America, with more than 160 locations in 25 states and Ontario, Canada. These vehicle centers, strategically located in high traffic areas on or near major highways throughout the United States and Ontario, Canada, represent truck and bus manufacturers, including Peterbilt, International, Hino, Isuzu, Ford, IC Bus and Blue Bird. They offer an integrated approach to meeting customer needs – from sales of new and used vehicles to aftermarket parts, service and body shop operations plus financing, insurance, leasing and rental. Rush Enterprises’ operations also provide CNG fuel systems (through its investment in Cummins Clean Fuel Technologies, Inc.), telematics products and other vehicle technologies, as well as vehicle up-fitting, chrome accessories and tires. For more information, please visit us at www.rushtruckcenters.com, www.rushenterprises.com and www.rushtruckcentersracing.com, on Twitter @rushtruckcenter and Facebook.com/rushtruckcenters.

Contact:
Rush Enterprises, Inc., New Braunfels, Texas
Steve Keller (830) 302-5226

NEW BRAUNFELS, Texas, Oct. 02, 2026 (GLOBE NEWSWIRE) — Rush Enterprises, Inc., (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America will host a conference call to discuss earnings for the third quarter 2026 on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central. Earnings will be reported after the close of market on Tuesday, October 27, 2026.

The call will be available at https://edge.media-server.com/mmc/p/exur5spz on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central.

Participants may register for the call at:
https://register-conf.media-server.com/register/BIb0ffed11621b4638812a165f5443c0ae
While not required, it is recommended that you join the event 10 minutes prior to the start.

For those who cannot listen to the live broadcast, the webcast replay will be available at http://investor.rushenterprises.com/events.cfm.

About Rush Enterprises, Inc.
Rush Enterprises, Inc. is the premier solutions provider to the commercial vehicle industry. The Company owns and operates Rush Truck Centers, the largest network of commercial vehicle dealerships in North America, with more than 160 locations in 25 states and Ontario, Canada. These vehicle centers, strategically located in high traffic areas on or near major highways throughout the United States and Ontario, Canada, represent truck and bus manufacturers, including Peterbilt, International, Hino, Isuzu, Ford, IC Bus and Blue Bird. They offer an integrated approach to meeting customer needs – from sales of new and used vehicles to aftermarket parts, service and body shop operations plus financing, insurance, leasing and rental. Rush Enterprises’ operations also provide CNG fuel systems (through its investment in Cummins Clean Fuel Technologies, Inc.), telematics products and other vehicle technologies, as well as vehicle up-fitting, chrome accessories and tires. For more information, please visit us at www.rushtruckcenters.com, www.rushenterprises.com and www.rushtruckcentersracing.com, on Twitter @rushtruckcenter and Facebook.com/rushtruckcenters.

Contact:
Rush Enterprises, Inc., New Braunfels, Texas
Steve Keller (830) 302-5226

NEW BRAUNFELS, Texas, Oct. 02, 2026 (GLOBE NEWSWIRE) — Rush Enterprises, Inc., (NASDAQ: RUSHA & RUSHB), which operates the largest network of commercial vehicle dealerships in North America will host a conference call to discuss earnings for the third quarter 2026 on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central. Earnings will be reported after the close of market on Tuesday, October 27, 2026.

The call will be available at https://edge.media-server.com/mmc/p/exur5spz on Wednesday, October 28, 2026 at 10:00 a.m. Eastern/9:00 a.m. Central.

Participants may register for the call at:
https://register-conf.media-server.com/register/BIb0ffed11621b4638812a165f5443c0ae
While not required, it is recommended that you join the event 10 minutes prior to the start.

For those who cannot listen to the live broadcast, the webcast replay will be available at http://investor.rushenterprises.com/events.cfm.

About Rush Enterprises, Inc.
Rush Enterprises, Inc. is the premier solutions provider to the commercial vehicle industry. The Company owns and operates Rush Truck Centers, the largest network of commercial vehicle dealerships in North America, with more than 160 locations in 25 states and Ontario, Canada. These vehicle centers, strategically located in high traffic areas on or near major highways throughout the United States and Ontario, Canada, represent truck and bus manufacturers, including Peterbilt, International, Hino, Isuzu, Ford, IC Bus and Blue Bird. They offer an integrated approach to meeting customer needs – from sales of new and used vehicles to aftermarket parts, service and body shop operations plus financing, insurance, leasing and rental. Rush Enterprises’ operations also provide CNG fuel systems (through its investment in Cummins Clean Fuel Technologies, Inc.), telematics products and other vehicle technologies, as well as vehicle up-fitting, chrome accessories and tires. For more information, please visit us at www.rushtruckcenters.com, www.rushenterprises.com and www.rushtruckcentersracing.com, on Twitter @rushtruckcenter and Facebook.com/rushtruckcenters.

Contact:
Rush Enterprises, Inc., New Braunfels, Texas
Steve Keller (830) 302-5226

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on October 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $89.93, the closing price per share of Spyre’s common stock as reported by Nasdaq on October 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on October 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $89.93, the closing price per share of Spyre’s common stock as reported by Nasdaq on October 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on October 1, 2026 and were material to each employee’s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $89.93, the closing price per share of Spyre’s common stock as reported by Nasdaq on October 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.

The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as amended and restated, which was adopted by the Board of Directors in September 2024 and amended in September 2026. The restricted stock awards will vest over three years in equal one-third increments on each of the first three (3) anniversaries of the grant date, subject to continued employment with the Company on each vesting date. The PSUs granted to Mr. Willard each represent a contingent right to receive one share of the Company’s common stock if predetermined levels of the Company’s total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029. The awards were granted as a material inducement to employment with PetMeds, in accordance with Nasdaq Listing Rule 5635(c)(4).

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com

DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment.

On September 28, 2026, PetMeds granted Jeff Willard, Chief Executive Officer and President, 250,000 shares of restricted common stock and 250,000 performance share units (“PSUs”), and on October 1, 2026, PetMeds granted Andrew Parry, Chief Technology Officer, 100,000 shares of restricted common stock.

The awards were granted pursuant to PetMeds’ 2024 Inducement Incentive Plan, as amended and restated, which was adopted by the Board of Directors in September 2024 and amended in September 2026. The restricted stock awards will vest over three years in equal one-third increments on each of the first three (3) anniversaries of the grant date, subject to continued employment with the Company on each vesting date. The PSUs granted to Mr. Willard each represent a contingent right to receive one share of the Company’s common stock if predetermined levels of the Company’s total shareholder return relative to the S&P 600 Specialty Retail Index are achieved over a three-year performance period ending on September 27, 2029. The awards were granted as a material inducement to employment with PetMeds, in accordance with Nasdaq Listing Rule 5635(c)(4).

About PetMeds

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PetMeds family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions — including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.

Investor Contact
ICR, LLC
Reed Anderson
investor@petmeds.com